Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Google Secures Pentagon AI Deal for Classified Projects 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
LEXINGTON, Mass., Feb. 01, 2016 -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that Dr. Ali Fattaey, President and Chief Executive Officer, will present at the BIO CEO & Investor Conference, February 8, 2016, at 5:30 p.m. Eastern Time in New York City.
A corresponding webcast of the presentation can be accessed by visiting:
http://www.veracast.com/webcasts/bio/ceoinvestor2016/89132240349.cfm
The webcast will be archived shortly after the live event and available for 30 days following the conference, and also available for 30 days on the Investor Relations section of the Curis website at www.curis.com.
About Curis, Inc.
Curis is a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907, a dual HDAC and PI3K inhibitor that is being investigated in two clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD-1 pathway/ VISTA, including PD-L1/VISTA antagonist CA-170, as well as to molecules designed to inhibit IRAK4. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma.
For more information, visit Curis' website at www.curis.com.
For More Information: Mani Mohindru, Ph.D. Senior Vice President, Corporate Strategy and Investor Relations Curis, Inc. 617-503-6605 [email protected] Media Contact David Schull Russo Partners (212) 845-4271 [email protected]
